PPARA and metabolic dysfunction-associated steatotic liver disease: Wy-14643 is a powerful PPARα agonist that can inhibit steatosis, restore insulin sensitivity, as well as lipid and adiponectin levels, thereby reducing MASLD caused by PPARα dysregulation (51).